KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short term Debt: 2023-2025

Historic Short term Debt for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Sep 2025 value amounting to $8.9 million.

  • Recursion Pharmaceuticals' Short term Debt rose 8.52% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 8.52%. This contributed to the annual value of $8.4 million for FY2024, which is 20448.78% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Short term Debt is $8.9 million, which was up 1.91% from $8.8 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Short term Debt's 5-year high stood at $8.9 million during Q3 2025, with a 5-year trough of $41,000 in Q4 2023.
  • Its 3-year average for Short term Debt is $7.3 million, with a median of $8.4 million in 2024.
  • Data for Recursion Pharmaceuticals' Short term Debt shows a peak YoY soared of 20,448.78% (in 2024) over the last 5 years.
  • Over the past 3 years, Recursion Pharmaceuticals' Short term Debt (Quarterly) stood at $41,000 in 2023, then spiked by 20,448.78% to $8.4 million in 2024, then grew by 8.52% to $8.9 million in 2025.
  • Its Short term Debt stands at $8.9 million for Q3 2025, versus $8.8 million for Q2 2025 and $8.6 million for Q1 2025.